Intellia Therapeutics (NTLA) Revenue: 2015-2025
Historic Revenue for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to $13.8 million.
- Intellia Therapeutics' Revenue rose 51.27% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.5 million, marking a year-over-year increase of 33.52%. This contributed to the annual value of $57.9 million for FY2024, which is 59.55% up from last year.
- Intellia Therapeutics' Revenue amounted to $13.8 million in Q3 2025, which was down 3.25% from $14.2 million recorded in Q2 2025.
- Over the past 5 years, Intellia Therapeutics' Revenue peaked at $28.9 million during Q1 2024, and registered a low of -$1.9 million during Q4 2023.
- Over the past 3 years, Intellia Therapeutics' median Revenue value was $12.9 million (recorded in 2024), while the average stood at $12.6 million.
- In the last 5 years, Intellia Therapeutics' Revenue skyrocketed by 4,322.00% in 2022 and then slumped by 114.12% in 2023.
- Over the past 5 years, Intellia Therapeutics' Revenue (Quarterly) stood at $12.9 million in 2021, then increased by 5.59% to $13.6 million in 2022, then crashed by 114.12% to -$1.9 million in 2023, then surged by 771.57% to $12.9 million in 2024, then spiked by 51.27% to $13.8 million in 2025.
- Its Revenue stands at $13.8 million for Q3 2025, versus $14.2 million for Q2 2025 and $16.6 million for Q1 2025.